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Abstract    
The E3 ubiquitin ligase RNF168 is a ring finger protein that has previously been 
identified to play an important regulatory role in the repair of double-strand DNA 
breaks.  In the present study, an unbiased forward genetics functional screen in 
mouse granulocyte/ macrophage progenitor cell line FDCP1 has identified E3 
ubiquitin ligase RNF168 as a key regulator of cell survival and proliferation. Our data 
indicate that RNF168 is an important component of the mechanisms controlling cell 
fate, not only in human and mouse haematopoietic growth factor-dependent cells, 
but also in the human breast epithelial cell line MCF-7. These observations therefore 
suggest that RNF168 provides a connection to key pathways controlling cell fate, 
potentially through interaction with PML nuclear bodies and/or epigenetic control of 
gene expression. Our study is the first to demonstrate a critical role for RNF168 in 
the in the mechanisms regulating cell proliferation and survival, in addition to its well-
established role in DNA repair.  
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Introduction 
The expression, replication and repair of DNA are pivotal to the physiological 
function of all cells. Understanding of the molecular mechanisms, control and 
integration of these processes is far from complete and this area is the subject of a 
great deal of research. This is justified, not only by the obvious importance of these 
processes in cellular physiology, but also by the many examples of abnormalities in 
these processes contributing to oncogenesis (reviewed by Hanahan & Weinberg [1]). 
The existence of important connections between DNA damage sensing mechanisms 
(DNA Damage Response – DDR) and control of gene expression and their impact 
on processes such as cell proliferation and differentiation have been suspected for 
several decades [2].  There is now direct molecular evidence for some of these 
mechanisms.  These range from DNA strand break-mediated activation of p53 
inhibiting hematopoietic progenitor cell differentiation [3,4] , and the induction of 
differentiation by specific DDR genes such as GADD45A in haematopoietic stem 
cells [5], to the involvement of CDK12 in the regulation of DDR and embryonic 
development [6]  as well as damage induced modulation of microRNAs that affect 
cell cycle progression, apoptosis and differentiation [7-9] . 
Ongoing progress in our understanding of gene expression, DNA replication and 
repair most often relies on detailed investigation of previously identified molecules 
and, as a consequence, generally progresses incrementally. By contrast, forward 
genetics strategies allow unbiased approaches that can identify key molecules 
involved in rate-limiting steps independently through the subversion of individual 
gene function [10]. Successful forward genetics strategies include cDNA functional 
expression cloning [11-16] and retroviral insertional mutagenesis [16-20]. Indeed, 
current retroviral insertional mutagenesis studies have focused attention on the role 
of E3 ubiquitin ligase RNF168 in the control of cell fate. 
Post-translational modification of proteins is extensively involved in controlling cell 
behaviour. Addition of ubiquitin to target proteins, either as a monomer or in the form 
of ubiquitin chains, is now recognised to have many important regulatory roles in 
addition to the targeting of proteins for degradation by the proteasome [21,22]. In 
particular, ubiquitination of nuclear proteins plays a central role both in DNA repair 
[22-24] and in epigenetic control of gene expression [26,27], including the expression 
of tumour suppressor genes [27].  
Extensive studies have implicated RNF168 in the repair of double-strand DNA break 
[23,28-32]. The repair of double strand DNA breaks is a complex process in which 
RNF168 and RNF8 catalyse the ubiquitination of histone H2A subtypes that leads to 
recruitment of protein components of the DNA repair machinery, including 53BP1 
and BRCA1 [28-32]. Mutation in RNF168 produces RIDDLE syndrome in humans 
[33], although some of the features of the phenotype, such as craniofacial 
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abnormalities and short stature, have hitherto been difficult to ascribe to aberrant 
DNA repair alone.  
Although RNF168 is amplified in some cancers [32,34], the observations reported 
below are the first to demonstrate the involvement of this gene in the control of cell 
survival and proliferation. Most recently, RNF168 has been shown to regulate PML 
nuclear bodies (PML NBs) [35], suggesting a potential mechanism for the regulation 
of proliferation and apoptosis by RNF168 described below. 
 
Materials and Methods 
Materials.  Recombinant mouse interleukin-3 (mIL-3) was obtained from R&D 
Systems (Abingdon, UK) and recombinant human interleukin-3 (hIL-3), reagents for 
RT-qPCR, Lipofectamine-2000 and the pcDNA3.1 and TopoPCR2.1 vectors were 
from Life Technologies Ltd (Paisley, UK). Cell culture reagents were from the latter 
source or from Sigma-Aldrich (Poole, UK). The plasmid pCMVSPORT6-RNF168 
(MGC: 45398; IMAGE 5163887), which contains the complete coding sequence of 
human RNF168, was from Source BioScience (Nottingham, UK) and nucleofector 
solution T was from Lonza Bioscience (Verviers, Belgium). QuikChange® XL Site-
directed Mutagenesis Kit was from Agilent Technologies (Stockport, UK) and 
polybrene was from Sigma-Aldrich (Poole, UK). siRNAs #1 - #4 to human RNF168 
(product codes: #1 = Hs_FLJ35794_1; #2 = Hs_RNF168_2; #3 = Hs_FLJ35794_3; 
#4 = Hs_RNF168_1) were from Qiagen Ltd (Crawley, UK); negative control (NC) 
siRNA (product 102728) and HiPerFect reagent were also from the latter source. 
The MTS assay kit (CellTiter 96 AQueous One Solution Cell Proliferation Assay) was 
from Promega (Southampton, UK) and the Muse Cell Cycle Assay Kit was from 
Millipore (UK) Ltd (Watford, UK). Protein Assay Kit II and pre-cast gels were from 
Bio-Rad Laboratories (Hemel Hempstead, UK). The RNF168 and beta-actin 
antibodies for immunoblotting were from Abcam (Cambridge, UK), whereas the anti-
myc and FITC-labeled anti-mouse IgG antibodies for immunofluorescence were from 
Santa Cruz Biotechnology (Heidelberg, Germany) and Sigma-Aldrich (Poole, UK), 
respectively. Hybond-P PVDF membranes were from Amersham Biosciences (Little 
Chalfont, UK). 
Cell culture.  The mouse haematopoietic granulocyte/ macrophage progenitor cell 
line FDCP1 [36-38] was maintained in RPMI-1640 medium supplemented with 10% 
foetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 
1 ng/ml recombinant mIL-3. Cells were deprived of mIL-3 by centrifugation and 
resuspension in mIL-3-free medium for 2 cycles of washing and cloning in soft agar 
without mIL-3. 293T cells were maintained in DMEM medium containing 10% foetal 
bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin.  TF-1 cells were 
routinely maintained in R-10 medium (comprises RPMI-1640 containing  2 mM L-
glutamine, 1 mM sodium pyruvate, 10 mM HEPES, 10% foetal calf serum and 50 
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µg/ml gentamicin) supplemented with recombinant hIL-3 (5 ng/ml) and MCF7 [39] 
cells were maintained in R-10 medium; all cells were cultured at 37 °C in a 
humidified incubator with 5% CO2. 
Generation of IL-3-independent FDCP-1B cell clones by retroviral insertional 
mutagenesis (RIM).  In this study the PAPM3P packaging cell line which produces 
M3Pneo-sup virus was used for infection of FDCP1B cells. For RIM, a total of 1x108 
cells were co-cultured with the irradiated PAP3MP packaging cells for 2 days in the 
presence of mIL-3. Then cells were harvested and incubated overnight in fresh 
medium also in the presence of IL-3. Next, while 1x108 cells were seeded in soft 
agar in the absence of mIL-3, 1x108 cells were taken through to the next round of co-
culture with the PAP3MP packaging cell line. These cycles of co-culture were 
repeated a total number of fifteen times. After each cycle 1x108 cells were cloned in 
soft-agar in the absence of mIL-3. A total of ninety-five IL-3 independent FDCP1B 
clones were isolated at the end of 15 rounds of co-culture. The IL-3 independent 
FDCP1B clones were initially expanded in 1 ml culture in the absence of mIL-3 and 
G418. Following their successful expansion, G418 selection was performed on all 
clones, each of which was found to be G418 resistant. In this study we have 
analysed one of these clones, referred to as PAP60 [40]. 
Inverse PCR (I-PCR).  The I-PCR method was performed as described earlier [41]. 
Briefly, genomic DNA of PAP60 cells was digested with the Sau3A restriction 
enzyme, followed by ligation and subsequent XbaI digestion. The sequence flanking 
the 3’ LTR of the integrated provirus in PAP60 was obtained using the outward 
directed primers MPSVA1 (AAACTGCTGAGGGCGGGACC) and MPSVA2 
(AGTTCGCTTCTCGCTTCTGT). The PCR fragments produced by I-PCR were 
cloned into the TopoPCR2.1 vector and the genomic DNA at the 3’ end of the 
integrated provirus flanking sequence was sequenced, i.e. 5’-  
GTAATTTCTTCTTTTAGCACTAAGAACTTTAGAAAGCTTTGTTAGGAGAAGGGTA
GCCTAAAGAATACTGAAAGAATAATTACAAAAATTCCTGTTCGGATC -3’ and 
identified by a BLAST search of the human genome.    
Plasmids and transfection.  Transduction into FDCP1B: All pLKO.1-shRNA 
plasmids were designed by The RNAi Consortium with the following clone reference 
numbers: control shRNA targeting GFP (shRNA-eGFP (SHC005)), and shRNA 
targeting mouse RNF168; shRNF168A (TRCN0000040876), shRNF168B 
(TRCN0000040873) (Open Biosystems).  
The coding sequence for full-length human RNF168 (IMAGE: BC046815) was 
subcloned into pcDNA3.1 plasmid in frame with a C-terminal Myc and His fusion 
domain; RNF168WT. The point mutations in the RING (RNF168H33A) and MIU 
domains (RNF168A179G/A450G) were introduced by site-directed mutagenesis 
using the QuikChange® XL Site-directed Mutagenesis Kit. All constructs were 
sequenced verified. 
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Transfection into TF-1 cells:  2 x 106 TF-1 cells, in 0.1 ml nucleofector solution T, 
were nucleofected with 2 µg plasmid constructs comprising pCMVSPORT6-RNF168 
or empty pCMVSPORT6 vector (for controls) using programme G-016, and cells 
were immediately plated in 3 ml I-20 medium (comprises Iscove's Modified 
Dulbecco's Medium containing 2 mM L-glutamine, 20% fetal bovine serum and 50 
µg/ml gentamicin) supplemented with hIL-3 (5 ng/ml) and allowed to recover for 20 h. 
Cells were then washed twice with R-10 medium, and resuspended (3 x 105 cells/ml) 
in R-10 medium ± hIL-3 (5 ng/ml) and cultured for a further 22 h before counting.  
RNA interference.  shRNA (LVshRNA):  Lentiviral vector was produced by transient 
co-transfection of 293T cells with lentiviral packaging plasmids; pCMVΔ8.91 and 
pMDG2 with the target lentiviral constructs; pLKO.1-shRNAs, using a calcium 
phosphate co-precipitation method. Supernatant, containing the vector, was 
harvested at 48 h (harvest I) and 72 h (harvest II). The vector supernatant was first 
clarified through a 0.45 μm filter and concentrated by centrifugation at 10,000g 
(Beckman J2-MC) overnight at 4oC, re-suspended in 500 µl RPMI-1640 medium and 
stored at -80oC. Cells were infected with lentivirus vectors in the presence of 4 µg/ml 
Polybrene.  A multiplicity of infection (moi) of 3 was used for infection. 
  siRNA: To determine the effect of RNF168 knockdown on culture growth, four 
siRNAs which target different portions of RNF168 sequence were individually 
studied, along with NC siRNA for controls. For TF1 cells, complexes were prepared 
by mixing 9 µl HiPerFect reagent with 209 µl siRNA (430 nM in OPTIMEM-I). After 
15 min, these were added dropwise to cells (4 x 105 cells in 0.2 ml R-10 medium with 
5 ng/ml IL-3; 12-well plates). After a further 3 h, R-10 medium with 5 ng/ml IL-3 (0.8 
ml) was added, and cells were cultured for a further 70 h to allow silencing to occur. 
Cells were then re-seeded (3 x 105 cells/ml R-10 medium with 5 ng/ml hIL-3) and 
cultured for a further 72 h to assay the growth parameters. For MCF7 cells, a fast-
forward transfection protocol was employed: complexes were prepared by mixing 12 
µl HiPerFect reagent with 100 µl siRNA (120 nM in OPTIMEM-I). After 15 min, these 
were added dropwise to freshly trypsinized, exponentially growing cells (1.5 x 105 
cells in 2.3 ml R-10 medium; 6-well plates) and these were cultured for 70 h. Cells 
were then re-plated in either fresh R-10 medium for MTS assay (0.5 x 104 cells/96-
well plate), direct cell counting and/or cell cycle analysis (both at 0.8 x 105 cells/12-
well plate) at the indicated times, or in R-10 medium supplemented with 10% cell-
conditioned medium (400 cells/6-well plate) for clonogenic assays.     
Real-time quantitative RT-PCR (RT-qPCR).  Total RNA was isolated using the 
TRIzol® reagent and 1 μg of purified total RNA from each sample was reverse 
transcribed to cDNA with oligo-dT primers by using a SuperScript IITM kit according 
to the manufacturer’s protocol. Quantitative PCRs were performed with Platinum® 
SYBR® Green qPCR SuperMix-UDG Kit (ThermoFisher Scientific) using an Applied 
Biosystems 7900 HT thermal cycler. The following primers were used: mouse 
RNF168 (5′-AGGCAGGTCTGAGGAGAAAGTGTT -3′, 5′-
AGGCAGGTCTGAGGAGAAAGTGTT -3′), mouse Smco1 (5′-
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ACCATGGAACTGAATATTGTATACAGCTAT -3′, 5′-
AACTGCTGGGTCAAAGGTAAC -3′) and beta-actin (5′-
TGAACCCTAAGGCCAACCGTGAAA -3′, 5′-AGTCCATCACAATGCCTGTGGTACG 
-3′). Cycling conditions were 5 min at 95°C followed by 40 cycles of 15 seconds at 
95°C, 30 seconds at 55°C, and 30 seconds at 72°C. The deltaCT method was 
applied to estimate relative transcript levels. Levels of beta-actin amplification were 
used as an endogenous reference to normalise each sample. 
Growth analyses.  Direct cell counting was performed after nigrosin blue (0.1% 
(w/v)) staining using a haemocytometer and light microscopy; cells which excluded 
the dye were considered to be viable. MTS assays were performed according to the 
manufacturer’s instructions. For clonogenic assays, the colonies formed following 3 
weeks of culture were counted after staining with crystal violet (0.5% (w/v) in 
methanol). Cell cycle analysis was performed on a Muse Cell Analyzer using a Muse 
Cell Cycle Assay Kit according to the supplied instructions. 
Immunofluorescence.  293T cells were cultured on glass coverslips in 6-well plates 
and transfected with pcDNA3.1/RNF168WT, RNF168H33A or 
RNF168A179G/A450G plasmid using Lipofectamine 2000 according to the 
manufacturer’s instructions. Thirty-six hours after transfection, cells were fixed in 4% 
paraformaldehyde for 30 min and permeabilized in 0.2% Triton-X 100 solution for 15 
min followed by blocking with 3% BSA/PBS for 30 min. For RNF168 protein 
detection by immunofluorescence, cells were incubated with mouse anti-myc primary 
antibody (1:200 dilution) for 1 hour then, after extensive washing, incubated with 
secondary antibody (FITC anti-mouse IgG, 1:100) for 1 hour, followed by washing 
with PBS. Coverslips were air-dried and counter-stained with DAPI. Images were 
acquired by fluorescence microscopy. 
Western blot analysis.  Whole protein lysates were extracted using RIPA lysis 
buffer supplemented with phenylmethylsulfonyl fluoride and protease inhibitor 
cocktail; the concentration of isolated proteins was determined using Protein Assay 
Kit II. Protein (50 µg) was electrophoresed (10% precast gel) then transferred to 
Hybond-P PVDF membranes. These membranes were incubated with anti-RNF168 
in 5% skimmed milk and appropriate secondary antibodies. Blots were then stripped 
and re-probed with an antibody to beta-actin. Western blot imaging and 
quantification was carried out using the LI-COR enhanced chemiluminescence 
system (LI-COR, Lincoln, USA). 
Statistical analyses.  Data are presented as the mean and standard error of the 
mean (SEM); the number of observations (n) refers to different transfected samples, 
each derived from a separate culture of cells. Data were analysed either by one-way 
analysis of variance, using either Bonferroni's multiple comparison test (MCT) or 
Dunnett’s MCT (the latter when comparing multiple groups versus a single group) for 
post-hoc analysis, or by two-way analysis of variance, using Dunnett’s MCT. 
Homogeneity of variance was checked by Bartlett's test and, where necessary, data 
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were transformed (log or square root) prior to analysis. All analyses were performed 
using GraphPad Prism v4.03. 
 
Results 
Retroviral insertional mutagenesis of mouse haematopoietic cells.  The FDCP1 
cell line is a growth factor-dependent haematopoietic granulocyte/ macrophage cell 
line originally isolated from DBA/2 mouse bone marrow [36]. FDCP1 cells were 
cloned using soft agar and limiting dilution in the presence of interleukin-3 (IL-3) and 
the sub-clone FDCP1B was selected for subsequent analyses because this sub-
clone undergoes apoptosis more rapidly and synchronously on withdrawal of IL-3 
[37] than parental FDCP1 cells [38].  
FDCP1B cells were infected with retrovirus M3Pneo-sup. M3Pneo-sup is a 
myeloproliferative sarcoma virus (MPSV)-based retroviral vector in which all viral 
genes have been removed (splice acceptor sequences and upstream sequences 
necessary for efficient splicing of Mo-MuLV are retained) and the selectable marker 
gene, neomycin phosphotransferase (neoR) has been inserted in order to select 
cells that carry an integrated provirus [42-44]. The retrovirally infected FDCP1B cells 
were plated in soft agar in the absence of IL-3 and IL-3 –independent clones were 
isolated. One of these clones, PAP60 [40], was selected for further study and 
showed complete IL-3-independence for both survival and growth (Fig. 1a). In order 
to determine whether the mutant cells could respond to IL-3 at all, they were 
challenged with topoisomerase II inhibitor etoposide in the presence and absence of 
IL-3 (Fig. 1b). The presence of IL-3 produced substantial protection against 
etoposide-induced apoptosis of both the PAP60 mutant cell line and the parental cell 
line, indicating that the PAP60 cell line retained responsiveness to IL-3 even though 
it was no longer IL-3-dependent for survival or proliferation. 
The key advantage of the retroviral insertional mutagenesis strategy is that it allows 
the site of insertion of the provirus to be determined by inverse PCR [41,45]. This 
technique revealed that, in the PAP60 cells, the provirus insertion site is in mouse 
chromosome 16, 229 bases upstream of the transcription start site of the gene 
encoding RNF168 (Fig. 2a), and 2,452 bases downstream of Smco1 
(2310010M20Rik), a 200 amino acid single-pass membrane protein. The human 
homolog of Smco1 is a 214 amino acid protein known as C3orf43 [46,47]. Since the 
effects of proviral integration are not entirely predictable, the transcription levels of 
the two genes flanking the integration site were determined by RT-qPCR in PAP60 
cells and the parental FDCP1B cells, both with and without IL-3 (Fig. 2b). The level 
of expression of Smco1 was the same in PAP60 and parental FDCP1B cells. By 
contrast, the level of expression of RNF168 was doubled in PAP60 cells relative to 
parental FDCP1B cells. The expression of the two genes examined was unaffected 
by the presence of IL-3 in both PAP60 and parental FDCP1B cells (Fig. 2b). Since 
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the exact mechanism by which retroviral insertion increases transcription from the 
nearby RNF168 gene is not clear, RNF168 mRNA levels were manipulated in other 
ways (see below).   
Analysis of the role of RNF168 in mouse cells.  Since the RT-qPCR analysis 
above suggested that RNF168 may be involved in the IL-3-independence observed 
in the PAP60 cells, the effect of down-regulation of endogenous RNF168 expression 
was examined. PAP60 and parental FDCP1B cells were transduced with shRNA 
vectors targeting RNF168. ShRNAs targeting GFP were used as a negative control. 
RNF168-targeting shRNAs reduced RNF168 mRNA levels by 60% – 70% in both 
PAP60 and FDCP1B cells (Fig. 3a). This was accompanied by substantial reductions 
in culture cell density for both RNF168 shRNAs (Fig. 3b), further implicating RNF168 
in the control of proliferation in these murine growth factor-dependent cells. This 
reduction in cell culture growth by both shRNF168 constructs was confirmed in a 
time-course experiment over 5 days (Fig. 3c). 
It is well-established that RNF168 plays a key role in the repair of double-stand DNA 
breaks through the ubiquitination of nuclear proteins [23,28,33,48-50]. In order to 
examine the possibility that RNF168 might also be involved in modification of 
proteins in other cellular locations, Myc-tagged RNF168 was expressed in 293T cells 
and examined by fluorescence microscopy. RNF168 could only be detected within 
the nucleus, with a speckled appearance (Supplementary Fig. 1). This nuclear 
distribution is consistent with the recently reported association of RNF168 with PML-
NB [35]. 
Analysis of the role of RNF168 in human haematopoietic cells.  In order to test 
the hypothesis that RNF168 might play a role in the regulation of growth factor-
dependence in human as well as mouse cells, we analysed the effect of over-
expression of RNF168 in the human growth factor-dependent cell line TF-1 [15]. TF-
1 is a human haematopoietic cell line and TF-1 cells are dependent on IL-3 or GM-
CSF for survival and proliferation [15]. TF-1 cells were transfected with a RNF168 
expression construct, in order to over-express RNF168, or with vector only (Fig. 4a). 
Transfected cells were incubated in the presence or absence of IL-3 for 22 hours; 
both culture viability and viable cell number in control vector-transfected TF-1 cells 
were significantly reduced in the absence of IL-3. By contrast, culture viability and 
viable cell number were unaffected by IL-3 withdrawal in the RNF168 over-
expressing TF-1 cells (Fig. 4b – d), as seen for PAP60 cells (Fig. 1), implicating 
RNF168 in the control of cell fate in human as well as mouse cells. Down-regulation 
of RNF168 in IL-3-supplemented TF-1 cells (Fig. 4e) produced reductions in both the 
total cell density and the viable cell density of cultures (Fig. 4f – h), further indicating 
a role for endogenous RNF168 in the proliferation of these human haematopoietic 
cells. 
Analysis of the role of RNF168 in human breast cancer cells.  Since both cell 
lines, mouse FDCP1B and human TF-1, are growth factor-dependent 
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haematopoietic cell lines, we extended the study to investigate the role of 
endogenous RNF168 in the proliferation and survival of human breast cell line MCF-
7. MCF-7 cell cultures were treated with siRNAs specific for RNF168, and a non-
targeting negative control siRNA. Western blotting confirmed partial depletion of 
RNF168 protein (Fig. 5a). RNF168 siRNAs significantly reduced MTS culture growth 
measurements and both viable cell density and total cell density (Fig. 5b – e). In 
addition, RNF168 siRNAs substantially reduced the colony-forming ability of MCF-7 
cells cloned 72 hours after treatment (Fig. 5f). Cell cycle analysis indicated that 
depletion of endogenous RNF168 increased accumulation of cells in the G0/G1 
phase, with corresponding decreases in cells in S phase and G2/M (Fig. 5 g – i). 
These consistent observations indicate that the involvement of RNF168 in the control 
of human cell proliferation is not restricted to haematopoietic growth factor-
dependent cells. 
 
Discussion 
A forward genetics strategy for the identification of functionally critical components of 
cell regulatory mechanisms has several important advantages: first, it is entirely 
independent of established knowledge; and second, it automatically focuses on 
elements that have controlling roles rather than on secondary phenomena [51-54]. 
Retroviral insertional mutagenesis is an important application of the forward genetics 
strategy that has identified many unanticipated genes that encode key components 
of the mechanisms regulating cell fate. Many of these genes are implicated in 
oncogenesis and/or resistance to cancer therapies [18,19]. Our unbiased screen for 
genes implicated in growth factor-independence in haematopoietic cells has 
identified an E3 ubiquitin ligase RNF168. 
RNF168 has a well-established and important role in the modification of 
chromosomal proteins required for the repair of double strand DNA breaks [23,28-
32]. The observations presented above strongly suggest a broader role in the 
regulation of cell fate, i.e. in controlling cell survival and proliferation (Figs. 1, 3, 4 
and 5). It is arguable that the amplification of RNF168 in tumours is consistent with 
this wider role [32,34]. The observation that overexpression of RNF168 confers 
growth factor-independence in both human and mouse haematopoietic cells (Figs. 1, 
3, 4 and 5) suggests its involvement at key stages in pathways controlling cell fate. 
Moreover, our data suggest that this involvement of RNF168 in cell proliferation and 
survival is not limited to the cells of the haematopoietic lineage as reduction in the 
endogenous expression of RNF168 significantly affects the survival, proliferation and 
colony-forming ability of human breast epithelial cell line MCF-7.  
Almost all previous reports of RNF168 activity have been concerned with the 
modification of nuclear proteins [31,55] and, consistent with this, our analysis of the 
subcellular localisation of RNF168 (Supplementary Fig. 1) indicates nuclear 
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localisation in patterns similar to those recently reported by Shire et al [35]. In this 
context it is important to appreciate that the post translational modification of 
chromosomal proteins, including by ubiquitination [56,57], is involved in the 
regulation of many cellular processes, and this includes gene expression as well as 
DNA repair. For example, Bhatnagar et al [27] reported that the ubiquitination of H2A 
by the E3 ubiquitin ligase TRIM37 resulted in the down-regulation of tumour 
suppressor genes in breast epithelial cells.  
Several recent papers have shown RNF168’s role extends beyond histone 
modification. As well as PML [35], RNF168-mediated ubiquitination of FOXM1 
[transcription factor forkhead box M1 [58] and TOP2α (topoisomerase IIα [59]) has 
also been demonstrated. The observation that RNF168 expression affects the 
accumulation of proteins in PML NBs may prove to be especially significant [35].  
Down-regulation of RNF168 increased the level of PML NBs and overexpression of 
RNF168 produced a corresponding decrease in PML NBs [35]. PML is a well-
established tumour suppressor [60-64] and a reduction or loss of expression of PML 
in other systems, e.g. in PML-/- mice, results in increased proliferation and reduced 
apoptosis [60-63]. In particular, in TF1 cells, expression of the PML–RAR alpha 
fusion protein, which acts as dominant negative PML [64], protects these cells from 
apoptosis induced by growth factor withdrawal, allowing growth factor-independent 
proliferation. Negative regulation of PML by RNF168 [35] could therefore account for 
the inhibition of apoptosis and growth factor independent proliferation that we report 
here. The functional importance of RNF168 in regulating cell proliferation and 
apoptosis may have important implications for the cell’s response to DNA damage. 
Through connecting the DNA repair process to PML-NB activity, RNF168 may help 
to link the DNA Damage Response to the subsequent fate of the cell. 
In summary, an unbiased functional screen identified RNF168 in mouse 
haematopoietic cell lines that survived and proliferated in the absence of growth 
factor. Subsequent experiments suggest that RNF168 may play  a key part of the 
mechanisms regulating cell survival and proliferation in both mouse and human cells, 
potentially through interaction with PML-NB. 
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Figure Legends 
FIG. 1.  RIM clone PAP60 is IL-3 independent for both survival and proliferation but 
is not insensitive to IL-3. (a) FDCP-1B and PAP60 cells were washed three times 
with RPMI-1640 medium lacking mIL-3 and then seeded at 1X105 cells per ml in the 
presence or absence of 1 ng/ml mIL-3. Cell proliferation was measured by MTT 
assay at the indicated time points over a 5 day period.   (b) The presence of IL-3 still 
exerts a strong protective affect for FDCP-1B and PAP60 cells when apoptosis is 
induced by etoposide treatments. FDCP-1B and PAP60 cells were washed and 
seeded at 2x105 cells in 2 ml culture medium, in the presence or absence of mIL-3 
with 3.4 μM etoposide (Eto). After 24 hours, cells were harvested, stained with 
propidium iodide, and apoptosis was detected using flow cytometry. Apoptotic bodies 
appear in the sub-G1 peak. Data are the mean ± S.D. of three independent 
experiments.  
FIG. 2. Identification of the provirus integration site in mouse chromosome 16 and 
expression of neighbouring genes. (a) Schematic representation of mouse 
chromosome 16, Smco1 and RNF168. In the PAP60 cells the provirus is integrated 
229 bases upstream of the 5’ transcription start site of the RNF168 and 2452 bp 
downstream of the 3’ end of the Smco1 gene. (b) Relative expression of Smco1 and 
RNF168 in FDCP-1B and PAP60 cells. PAP60 and FDCP1B cells were grown in the 
presence (1 ng/ml) of mIL-3 for 48 hours. The cells were then washed and grown in 
the presence or absence of mIL-3 for 12 hours. mRNA expression of Smco1 and 
RNF168 in parental FDCP-1B cells and PAP60 cells in the presence (1 ng/ml) or 
absence of mIL-3 were analyzed by reverse-transcription and real-time PCR with 
specific primers to Smco1, RNF168 and beta-actin. The transcript levels are 
expressed relative to β-actin mRNA levels in the parental FDCP-1B cells. RT-qPCR 
measurements were repeated three times with similar results. 
 
FIG. 3.  Downregulation of RNF168 in FDCP-1B and PAP60 cells leads to reduced 
numbers of cells. (a and b) FDCP-1B and PAP60 cells were transduced with LV-
shRNF168A, LV-shRNF168B and LV-shGFP (MIO=3). (a) RNA levels and (b) cell 
density were determined on day 4 after transduction. Data are expressed as mean ± 
SD, and statistical analyses of the data were performed using student’s t test. Values 
of P<0.05 were considered to be statistically significant. The data are representative 
of three independent experiments for FDCP-1B and two independent experiments 
for PAP60 cells. (a) RNF168 RNA levels are expressed relative to the levels in the 
untreated corresponding cell line (PAP60 absolute level is 2-fold higher than FDCP1 
absolute level Fig. 2b). (c) Reduction in cell number by downregulation of RNF168. 
FDCP-1B and PAP60 cells were transduced with LV-shRNF168A, LV-shRNF168B 
and LV-shGFP vectors, at an MOI of 3. Cell numbers were determined by MTT 
assay over an 8 day period. Data are expressed as a percentage MTT activity 
compared with non-infected cells. 
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FIG. 4. RNF168 regulates the growth and survival of the human growth factor-
dependent cell line, TF1. Cells were either transfected with a plasmid encoding 
human RNF168 or siRNA to human RNF168 and then cultured in the absence or 
presence of IL-3. (a - d) Cells were nucleofected with the plasmids pCMVSPORT6-
RNF168 (R) or pCMVSPORT6 alone (V) and maintained in the presence of IL-3 for 
20 h. (a) Western blot analysis demonstrating upregulation of RNF168. Cells were 
then washed and re-plated at equal densities in medium containing (+) or without (-) 
IL-3 and cultured for a further 22 h before determining culture viability (panel b), 
viable cell number (panel c) and total cell number (panel d). Note that vector-
transfected cells only demonstrate IL-3 dependence and that overexpression of 
RNF168 increases culture growth/viability in the absence of IL-3 only (*P < 0.05 & 
***P < 0.001 for intra-plasmid comparisons; ^P < 0.05 & ^^^P < 0.001 for inter-
plasmid comparisons; one-way ANOVA and Bonferroni’s MCT; n = 5). (e - h) Cells 
were transfected with one of four different siRNAs to RNF168 (#1 - #4) or with 
negative control (NC) siRNA and maintained in the presence of IL-3 for 70 h. (e) 
Western blot analysis demonstrating downregulation of RNF168. Cells were then 
washed and re-plated at equal densities in medium containing IL-3 and cultured for a 
further 70 h before determining culture viability (panel f), viable cell number (panel g) 
and total cell number (panel h). Note that silencing of RNF168 reduces culture 
growth (*P < 0.05 & **P < 0.01 versus NC siRNA-transfected cells; one-way ANOVA 
and Dunnett’s MCT; n = 5). 
 
FIG. 5. RNF168 also regulates the growth of human growth factor-independent cells. 
The breast cancer cell line, MCF7, was transfected with one of four different siRNAs 
to RNF168 (#1 - #4) or with negative control (NC) siRNA and, after 70 h, cells were 
re-plated at equal densities for analyses of culture growth and the cell cycle. (a) 
Western blot analysis demonstrating the effectiveness of the treatments. (b - d) 
Culture growth parameters determined by direct microscopic counting at 48 h post-
replating. Note that silencing of RNF168 has negligible effect on culture viability 
(panel b) but significantly reduces viable (panel c) and total (panel d) cell numbers 
(*P < 0.05 & **P < 0.01 versus NC siRNA-transfected cells; one-way ANOVA and 
Dunnett’s MCT; n ≥ 3). (e) MTS assay of culture growth up to 96 h post-plating 
confirming reduced growth of cells transfected with siRNA to RNF168; statistical 
analysis (two-way ANOVA and Dunnett’s MCT; n ≥ 3) demonstrates different (P < 
0.05) values for all siRNAs at 72 h and for siRNAs #3 and #4 at 96 h. (f) Clonogenic 
assay data demonstrating that long-term growth of cells is compromised following 
silencing of RNF168 (*P < 0.05 & **P < 0.01 versus NC siRNA-transfected cells; 
one-way ANOVA and Dunnett’s MCT; n ≥ 3). (g - i) Cell cycle analysis at 24 h post-
replating, indicating reduced proliferation following silencing of RNF168 (*P < 0.05, 
**P < 0.01 & ***P < 0.001 versus NC siRNA-transfected cells; one-way ANOVA and 
Dunnett’s MCT; n = 3) 
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Supplemental Material For Publication 
Supplementary Figure 1. Subcellular localization of RNF168. Myc-tagged wild-type 
(RNF168WT), RING domain mutated (RNF168H33A) and MIU domains mutated 
(RNF168A179G/A450G) RNF168 plasmids were transfected into 293T cells. 
RNF168 protein was visualized using anti-myc antibody; nuclei were counter stained 
with DAPI. RNF168WT (A) and RNF168H33A (B) proteins localized to nucleus with 
a dot-like, speckled pattern, while RNF168A179G/A450G (C) distributed evenly 
throughout the nucleus. 
 
 
 
 
 
